MNM at the ESMO 2022 Congress

September 15, 2022
No items found.

At ESMO 2022 Congress in Paris the era of AI deployment continues.

Klaudia Pacewicz and Paulina Nawrocka-Muszynska presented preliminary findings showing how machine learning algorithms can predict response to immune checkpoint inhibitors (ICIs) with greater precision than any standard biomarkers. Our algorithm developed on non-small-cell lung carcinoma patients treated with pembrolizumab/nivolumab achieved great results with an accuracy of 0.88.

Incredible data emphasizing the power of genomic-based and AI research presented at ESMO makes us extremely excited about the future of the fight against cancer. We are so proud that our work actively contributes to the development of innovative medicine.

MNM at the ESMO 2022 Congress
September 22, 2022

You may also like

MNM at the ESMO 2022 Congress

At ESMO 2022 Congress in Paris the era of AI deployment continues.

MNM's platform ARETE works!

MNM's platform ARETE - a proprietary AI technology designed for cancer genomics has been successfully externally validated by one of our Partners.

Publication in Molecular Diagnosis & Therapy has been just released

MNM Biosciences, in co-operation with leading Polish cancer centers, has recently published a breakthrough publication concerning breast cancer diagnostics.

5th DNA Repair/Replication Structures and Cancer Conference

MNM Bioscience presents its participation in the fifth DNA Repair/Replication Structures & Cancer conference (27 Apr 2022 – 01 May 2022), where speakers will focus on presenting the structural and mechanistic insights of dynamic complexes, operating in DNA repair and replication, transcription and other cancer-relevant events.